Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection, Nancy G. Klimas, A. J. Rodger, Z. Fox, J. D. Lundgren, L. H. Kuller, C. Boesecke, D. Gey, A. Skoutelis, M. B. Goetz, A. N. Phillips, INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group
Faculty Articles

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up, Nancy G. Klimas, J. D. Lundgren, A. Babiker, W. El-Sadr, S. Emery, B. Grund, J. D. Neaton, J. Neuhaus, A. Phillips
Faculty Articles

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial, Nancy G. Klimas, W. M. El-Sadr, B. Grund, J. Neuhaus, A. Babiker, C. J. Cohen, J. Darbyshire, S. Emery, J. D. Lundgren, A. Phillips, J. D. Neaton
Faculty Articles

Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2, Z. Fox, F. Antunes, R. Davey, B. Gazzard, Nancy G. Klimas, A. Labriola, M. Losso, J. D. Neaton, A. N. Phillips, K. Ruxrungtham, S. Staszewski, L. Weiss, J. D. Lundgren
Faculty Articles